Supporting Therapy Platform Development with Advanced Characterization of Engineered T Cells via Single-cell Sequencing and Flow Cytometry

Here, we profile and characterize >32,000 engineered T cells from two donors exposed to antigen positive target cells. We identify a critical need to combine flow cytometry and scRNA-seq for robust cell therapy characterization. This adaptable, dual approach provides a multi-omic view, linking functional protein expression at the cell surface with the underlying transcriptional landscape. This synergy offers superior insight into cell characterization, transduction, and potency, enabling the development of more effective cell and gene therapies.